The Latest News

2017第20届中国临床肿瘤协会年会 USCACA-CSCO联合专场:国际新药研究中国化 中国新药研究国际化

第20届中国临床肿瘤协会年会在厦门召开,在本次大会上,由美中抗癌协会、中国临床肿瘤协会新药研发及安全性评估专业委员会主办的USCACA-CSCO联合专场,于大会的第二天,2017年9月28日下午,在厦门国际会展中心成功举行。本次联合专场的主题是:TranslatingScience into Medicine - Cancer Drug Development of Immuno-oncology Combinationand Novel Targeted Agents。一如往年的火爆场面,能容纳200多位听众的会场,座无虚席,不少听众在会议开始前1个多小时,就早早地占据了最好的座位,晚来的很多听众,只能在会场后面站着听。

1
2
3

CJC: Our journal has an Impact Factor of 4.111 now, a big jump in History

We are pleased to announce that the 2016 Impact Factor (IF) of Chinese Journal of Cancer (CJC) is 4.111 according to the Journal Citation Reports released by the Clarivate Analytics on June 14, 2017.

A Big Jump

USCACA Participate in the Up-coming 20 CSCO Annual Meeting in Xiamen

USCACA will participate in the upcoming 20th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) (http://reg.csco.org.cn/reg2017en/) with a theme of "Together we innovate on our inheritance", to be held on Sept. 26-30, 2017 at Xiamen International Conference and Exhibition Center, Xiamen, Fujian, China. USCACA-CSCO will have a session entitled "Translating Science into Medicine – Early Phase Cancer Drug Development of Immuno-­‐oncology Combinations and Novel Targeted Agents” to be chaired by Helen Chen and Li Yan.

USCACA-CSCO Joint Session

Congratulations to the newly elected President Shi-Yuan Cheng at the ACACR Inaugural Meeting, April 2, 2017, Washington DC

Shiyuan Cheng, Professor at Feinberg School of Medicine of Northwestern University was elected as the new President of the newly formed Association for Chinese Americans in Cancer Research (ACACR) at the Inaugural Meeting, April 2, 2017 (also a joint meeting of USCACA and ACACR) at the 2017 AACR Annual meeting in Washington DC. Shi-Yuan was also the past President of USCACA (2013-2016), and his outstanding service for USCACA was recognized by an outstanding service plate presented by his successor, Qingyi Wei, the new President of USCACA.

USCACA Welcomes Its New President - Qingyi Wei

Qingyi Wei, Professor at Duke University School of Medicine was elected to be the new president of USCACA at the joint meeting of USCACA and ACACR at the 2017 AACR Annual meeting in Washington DC.

魏庆义,男,1983年获南京医科大学医学学士学位,1987年获中国预防医学科学院环境毒理学硕士学位,1992年5月获美国霍普金斯大学公共卫生学院博士学位。先后为美国M.D.Anderson癌症中心助理教授、副教授和终身教授以及冠名教授,杜克大学医学院医学系教授和美国NIH多个基金评审组成员、国际多个分子流行病学和医学杂志的主编(Cancer Medicine)、副主编 (International Journal of Molecular Epidemiology and Genetics)和编委,为20余种专业杂志的审稿人以及英国、德国、意大利、以色列、香港等国家和地区国家级科研基金评审人。


中国原创三代EGFR-TKI,期待中的下一个“明星”


在刚刚闭幕的IASLC WCLC 2016上,靶向药物无疑再次捍卫了其在晚期非小细胞肺癌(NSCLC)治疗领域的“明星”地位。新型靶点的探索,传统药物新治疗领域的拓展,液体检测在靶向药物疗效预测中的价值等研究,纷纷登录主席专场、口头报告、壁报等各种展示环节。

12月7日,在“靶向治疗新策略”口头报告环节发布的一项“突变选择性EGFR抑制剂AC0010(艾维替尼)在EGRF T790M非小细胞肺癌患者中的I、II期研究”,因其使用中国首个原创三代EGFR-TKI药物而备受关注。



第五届广州国际肿瘤学会议开幕: 关注学科发展前沿,加强国内外学术交流



本报讯 12月1日,由广东省抗癌协会、中国抗癌协会肿瘤靶向治疗专业委员会、美中抗癌协会、中山大学肿瘤防治中心、《癌症》杂志共同主办的“第五届广州国际肿瘤学会议暨第一届中国抗癌协会肿瘤靶向治疗专业委员会年会”在绿意盎然的羊城广州召开。

经历既往4届会议的铺垫与积累,“关注学科发展前沿,加强国内外学术交流”已经成为广州国际肿瘤学会议的主旨。本次为期3天的会议,邀请多名中外院士、200余位国内外肿瘤专家出席、参会演讲;通过全体大会、国际专场、学术报告,壁报讨论等环节,为2000余位从事肿瘤学研究和防治相关工作的参会学者,提供展示、学习和交流的平台。


Application Guidelines Asian Fund for Cancer Research

Application Guidelines Asian Fund for Cancer Research

Funding Period: April 1, 2017 – March 31, 2019 October, 2016


浙江省肿瘤防治联盟成立 美尊医询升级中美医疗沟通效率


2016年10月15-16日,由中国肿瘤防治联盟浙江省联盟筹委会与浙江省肿瘤靶向治疗技术指导中心筹委会共同主办,美中抗癌协会(USCACA)协办的中国肿瘤防治联盟浙江省联盟暨浙江省肿瘤靶向治疗技术指导中心成立大会,在浙江杭州邵逸夫医院下沙院区圆满召开。近200位顶级肿瘤专科专家参会。作为专注于管理中美肿瘤治疗资源的移动智慧医疗服务平台,美尊医询全程助力大会召开,连接美方高端专家资源,提升中美医学交流水平!


行业聚焦:打造中美肿瘤医疗连接平台的呼声


Partnership for 5 more years

Dr. George Wilding, a Board Member of USCACA and the Vice Provost of MD Anderson Cancer Center, led a delegation to attend the 2nd International Conference on Translational Cancer Research held in Tianjin during August 2016. Dr. Wilding and Dr. Ping Wang, the President of Tianjin Medical University Cancer Hospital and Institute, also signed an Agreement to continue the Sister Institute Relationship for 5 additional years after 10 years’ highly successful partnership.


Pages